Strategic Collaborations

Program Partner Indication Phase Platform Description

QC / CMC
Pre-Clinical/ Clinical Phase: Phase I-IV/ Market
Analytical services for CMC activities
Contract Research Organization. AnaBioTec offers in-depth product knowledge & drug development expertise. With an early development and well established GMP compliant platform, AnaBioTec provides analytical services for all CMC activities. Contact information: jessika.wynendaele@anacura.com.

RNA manufacturing
Products and process technology
The formation of AuroRNA Biotech with China Grand Pharma provides eTheRNA access to the Greater China market for selected mRNA cancer and infectious disease vaccine programmes, its proprietary mRNA formulation technologies and GMP manufacturing process technology.
A008

HIV
Discovery
mRNA, Adjuvant & Delivery Formulation
Development of an HIV vaccine based on ConserV's proprietary HIV antigens and eTheRNA's proprietary mRNA, adjuvant and LNP technologies.
A002

HPV+ Cancers
Preclinical

TIGER grant of EUR 6.9 million from the EU commission was awarded to a consortium led by eTheRNA. The grant will be used to accelerate A002. Collaborators include:

  1. Amsterdam UMC (Netherlands)
  2. BiotechSubsidy (Belgium)
  3. Ceratium B.V. (Netherlands)
  4. eTheRNA immunotherapies NV (Belgium)
  5. European Cancer Patient Coalition (Belgium)
  6. Radiomics (Belgium)
  7. SAGA Diagnostics AB (Sweden)
  8. Saint-Luc University Clinics (Belgium)

RNA manufacturing
Content
Process Engineering
Contract manufacturing
A005

Kidney Cancer
Discovery
mRNA, Adjuvant & Delivery Formulation
Development of a therapeutic renal cell carcinoma vaccine based on Frame's proprietary shared frameshift neoantigens and eTheRNA's proprietary mRNA, adjuvant and LNP technologies.

LNP technology
Discovery
Lipid Chemistry & Delivery Formulation
eTheRNA has exclusive worldwide rights to commercialise a new library of novel ionizable lipids, co-developed with the research group of Prof. Bruno De Geest from Ghent University, for a new generation of lipid nanoparticle (LNP) formulations.
A007

Malaria
Discovery
mRNA, Adjuvant & Delivery Formulation
Development of a malaria vaccine based on Institut Pasteur's proprietary malaria antigens and eTheRNA's proprietary mRNA, adjuvant and LNP technologies.
A006

SARS-CoV-2
Discovery
Delivery Formulation
Development of a SARS-CoV-2 vaccine based on eTheRNA's proprietary mRNA, adjuvant and LNP technologies and including SARS-CoV-2 T-cell epitopes identified using myNEO's proprietary antigen prediction algorithms.
A002

HPV+ Cancers
Preclinical
Process technology
Spray drying

mRNA technology
Lipid Chemistry & Delivery Formulation
The collaboration aims to improve the mRNA translation efficiency and, as such, overall efficacy of locally administered mRNA therapies by combining eTheRNA's proprietary mRNA technologies with PCI Biotech's proprietary photochemical internalisation technology.

RNA manufacturing
Process Engineering
Contract development and supply of SUM

RNA Production System
Process technology
Quantoom and eTheRNA are working to build a small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need. Unlike large and costly existing RNA production plants, the RPS will manufacture RNA small modular units, which can be shipped easily across multiple geographic regions. The RPS is intended to be scaled seamlessly from small scale preclinical batches to mass production of GMP-grade RNA. The only requirement will be for the RPS to be located inside a suitable clean room with an uninterrupted utility supply.

RNA manufacturing
Process Engineering
Delivery of process components

TriMix and TetraMix
A002

HPV+ Cancers
Preclinical
Process Engineering
Spray drying

undisclosed
Discovery
mRNA, Adjuvant & Delivery Formulation
Development of a self-amplifying mRNA platform

undisclosed
Discovery
Process technology
Evaluation of linear DNA as a template for mRNA production.